As health care systems around the world face challenges such as labor shortages, increased regulation and budget constraints, they rely on technology to help manage the impact. To assist in addressing these challenges, Abbott announced OneLab, a new, Web-based, integrated laboratory informatics solution.

Boehringer Ingelheim has established a translational research collaboration with the Presidents and Fellows of Harvard College. The goal of the collaboration is for the scientists of Boehringer Ingelheim to work together with the scientific community of Harvard to advance our knowledge in areas of high unmet medical need.

Seven pharmaceutical companies and four research institutions, working with the Bill & Melinda Gates Foundation, have launched a ground breaking partnership that aims to speed the discovery of essential new treatments for tuberculosis (TB).

Bristol-Myers Squibb Company (NYSE: BMY) and Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) announced that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion.

Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.

Roche site in Nutley (New Jersey, USA) to be closed - respective R&D activities to be consolidated in Switzerland and Germany. The planned site consolidation and the streamlining of research activities within Roche's Pharma Research and Early Development unit to support efficient allocation of resources for the Group's expanding product development pipeline.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that people with HER-2 positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of PerjetaTM (pertuzumab), Herceptin® (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.